Evidence map›Paper›PMID 32387130›Full record

ArticleImmunobiology2020

GTS-21, an α7nAChR agonist, suppressed the production of key inflammatory mediators by PBMCs that are elevated in COPD patients and associated with impaired lung function.

Sana Douaoui, Reda Djidjik, Mokhtar Boubakeur, Merzak Ghernaout, Chafia Touil-Boukoffa, Mustapha Oumouna, Fawzi Derrar, Yassine Amrani

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Immunobiology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed, 1 pooled it
1.0field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 1 synthesis or guideline pooled it, 18 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. Review
  10. Review
  11. Article
  12. Review
  13. Nicotinic Receptor Subunits Atlas in the Adult Human Lung.International journal of molecular sciences · 2020
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 5 institutions in 2 countries.

Sana DouaouiUSTHB, Cytokines and NO Synthases' Team, LBCM, FSB, Algiers, Algeria; Faculty of Sciences, Department of Life and Natural Sciences, University of Medea, Algeria.
Reda DjidjikDepartment of Immunology, Issaad Hassani Hospital, Beni Messous, Algiers, Algeria.
Mokhtar BoubakeurDepartment of Pneumology & Phtisiology, and Allergology, Rouiba Hospital, Algiers, University of Algiers 1, Faculty of Medicine, Algiers, Algeria.
Merzak GhernaoutDepartment of Pneumology & Phtisiology, and Allergology, Rouiba Hospital, Algiers, University of Algiers 1, Faculty of Medicine, Algiers, Algeria.
Chafia Touil-BoukoffaUSTHB, Cytokines and NO Synthases' Team, LBCM, FSB, Algiers, Algeria.
Mustapha OumounaFaculty of Sciences, Department of Life and Natural Sciences, University of Medea, Algeria.
Fawzi DerrarNational Influenza Centre, Viral Respiratory Laboratory, Pasteur Institute, Algiers, Algeria.
Yassine AmraniDepartment of Respiratory Sciences, Institute of Lung Health and NIHR Leicester BRC-Respiratory, Glenfield Hospital, University of Leicester, Leicester, UK. Electronic address: ya26@le.ac.uk.
University of Algiers Benyoucef Benkhedda · DZGlenfield Hospital · GBInstitut Pasteur d'Algérie · DZUniversity of Sciences and Technology Houari Boumediene · DZUniversity Yahia Fares of Medea · DZ

Funding

Department of Health
6 · The paper itself

Abstract

Chronic obstructive pulmonary disease (COPD) is a lung inflammatory disease characterized by progressive airflow limitation, chronic respiratory symptoms and frequent exacerbations. There is an unmet need to identify novel therapeutic alternatives beside bronchodilators that prevent disease progression. Levels of both Nitric Oxide (NO) and IL-6 were significantly increased in the plasma of patients in the exacerbation phase (ECOPD, n = 13) when compared to patients in the stable phase (SCOPD, n = 38). Levels of both NO and IL-6 were also found to inversely correlate with impaired lung function (%FEV1 predicted). In addition, there was a strong positive correlation between levels of IL-6 and NO found in the plasma of patients and those spontaneously produced by their peripheral blood mononuclear cells (PBMCs), identifying these cells as a major source of these key inflammatory mediators in COPD. GTS-21, an agonist for the alpha 7 nicotinic receptors (α7nAChR), was found to exert immune-modulatory actions in PBMCs of COPD patients by suppressing the production of IL-6 and NO. This study provides the first evidence supporting the therapeutic potential of α7nAChR agonists in COPD due to their ability to suppress the production of key inflammatory markers associated with disease severity.

Indexed as

Agedalpha7 Nicotinic Acetylcholine ReceptorBenzylidene CompoundsBiomarkersCytokinesDisease ProgressionFemaleHumansInflammation MediatorsLeukocytes, MononuclearMaleMiddle AgedNitric OxidePulmonary Disease, Chronic ObstructivePyridinesRespiratory Function Tests3-(2,4-dimethoxybenzylidene)anabaseinealpha7 Nicotinic Acetylcholine ReceptorBenzylidene CompoundsBiomarkersCytokinesInflammation MediatorsNitric OxidePyridinesCOPD pathogenesisIL-6Nicotinic receptorsNitric oxideSystemic inflammation

Identifiers

PMID32387130
PMCPMC7194070
OpenAlexW3022510323

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.